Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Intratus-Nevada Inc. focuses its patent portfolio on the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action under review. This prosecution activity involves 1 distinct examiner and is located within 1 distinct art unit. This indicates a very specific focus for the company's current intellectual property efforts, with all activity concentrated in a single area of the USPTO.
SIMMONS, CHRIS E is the busiest examiner for this portfolio, managing 1 pending office action. As the only examiner currently reviewing the company's work, this individual's interpretation of Biotechnology & Pharmaceuticals standards is critical. For a practitioner, this means that the prosecution strategy must be specifically aligned with the expectations of SIMMONS, CHRIS E, as there are no other examiners to provide alternative perspectives.
The presence of 1 pending office action in 1 distinct art unit means that the company's current patent trajectory is highly dependent on a single set of results. There is no broader portfolio activity to mitigate the impact of a single examiner's decision. Consequently, the company's success in securing its intellectual property relies on the successful navigation of the specific requirements set forth in the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SIMMONS, CHRIS E | 1 | 34.1% | +19.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17466050 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, HYPEROPIA, ASTIGMATISM, DECREASED STEREOPSIS, AND DECREASED CONTRAST SENSITIVITY | SIMMONS, CHRIS E | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17466050 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA, HYPEROPIA, ASTIGMATISM, DECREASED STEREOPSIS, AND DECREASED CONTRAST SENSITIVITY | SIMMONS, CHRIS E | 1622 | §103DP | Final Rejection | — | Pending | Sep 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial